Steven P. Rowe, MD, PhD

Steven Rowe, MD, PhD, gives an overview of current data on prostate-specific membrane antigen (PSMA)-targeted PET imaging for initial staging of prostate cancer (PCa) and evaluation of recurrent disease. He emphasizes PSMA’s limited sensitivity for initial diagnosis and high sensitivity for recurrent disease, while also noting potential strengths and weaknesses of PSMA that are independent of sensitivity.